Cure My Disease

Don't miss your cure!

 Log in / Sign up

A phone app takes on depression: can digital therapy enhance brain stimulation?

NCT ID NCT07792252

Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

Researchers at Yale are studying whether a prescription app called Rejoyn, which provides cognitive behavioral therapy exercises, can be a useful addition to standard depression treatments like TMS or esketamine. The study will enroll 50 adults with major depressive disorder who are already taking antidepressants and receiving or starting these interventional treatments. The team will track how often participants use the app and whether their depression symptoms change over time. This is an observational study, meaning the app is prescribed as part of usual care, and the researchers simply watch what happens.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rejoyn, a prescription digital therapeutic app that delivers cognitive behavioral therapy exercises
What this could lead to
If it works, Rejoyn could become a standard add-on to brain-stimulation treatments, helping people with depression get more benefit from their care.
What could go wrong
This is a small observational study, not a controlled trial, so it cannot prove the app causes improvement. People may not use the app as directed, and results may not apply to other clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults diagnosed with MDD who are receiving intranasal esketamine or TMS.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinician-confirmed diagnosis of Major Depressive Disorder * Currently being treated with an antidepressant medication * Currently receiving or initiating TMS or esketamine at YNHH IPS * For those receiving TMS, they must be able to initiate Rejoyn within the first two weeks of beginning TMS * Experiencing at least mild depressive symptoms as defined by QIDS of ≥6 * Clinician determines patient is appropriate for Rejoyn and prescribes it as part of standard care * Able to access and use a compatible smartphone * Able to provide informed consent for use of clinical data in research Exclusion Criteria: * Clinician determines Rejoyn is not suitable or safe for the patient * Significant cognitive impairment that prevents app use * Insufficient English proficiency to use Rejoyn * Concurrent participation in another interventional study that would interfere with naturalistic data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yale Greenwich Hospital Interventional Psychiatry Services

    Greenwich, Connecticut, 06830, United States

  • Yale New Haven Hospital Interventional Psychiatry Services

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.